ドロップダウンアイコン
ドロップダウンアイコン
ドロップダウンアイコン
JP
/
EN
メニューアイコン
Media
Nikkei Ranks Craif Top of the Bio and Medical Device Category in Its 2025 NEXT Unicorn Survey of Unlisted Japanese Companies
2026.01.22

The survey is Nikkei's own estimate of the value and growth of privately held Japanese companies.

TOKYO, January 22, 2026 - Craif Inc., a bio-AI company developing a urine analysis platform for early detection of cancer and other diseases, was placed first in the bio and medical device category of the 2025 NEXT Unicorn Survey compiled by Nikkei Inc., the publisher of the Nihon Keizai Shimbun, Japan's largest business daily. Nikkei published the survey on January 19, 2026. The survey is available at https://vdata.nikkei.com/newsgraphics/next-unicorn/#/dataset/2025/list?about=true

The NEXT Unicorn Survey ranks unlisted Japanese companies.

Nikkei surveyed startups aiming to become unicorns, meaning unlisted companies with an enterprise value of $1 billion (approximately ¥144 billion) or more, independently estimated their valuations, and ranked them by sector.

The ranking reflects Nikkei's independent assessment. It is not a financing round or a valuation disclosed by Craif, and it does not indicate that Craif has reached unicorn status.

About Craif

Craif is a bio-AI company founded in 2018 that develops non-invasive tests for the early detection of cancer. Its platform combines proprietary biomarker detection from urine and other bodily fluids with AI to assess disease risk. Building on one of the world's largest urine datasets, Craif aims to create a urine analysis platform that detects a wide range of diseases early, with cancer as the first step. The company is based in Tokyo and operates a wholly owned laboratory in San Diego, opened in 2026. Learn more at craif.com.

Media contact

press_us@craif.com